论文部分内容阅读
目的:研究C-Kit在腹泻型肠易激综合征(IBS-D)肥大细胞(MC)中的表达情况,为临床个体化诊治提供依据。方法:对2007-01~2007-05于包头医学院第二附属医院内蒙古消化病研究所依RomeIII确诊的56例IBS-D病人,免疫组化采用EnVision法检测肠黏膜不同部位C-Kit在MC中的表达情况。结果:病例组C-kit在MC中高表达者32例,其中回盲部、升结肠MC数量明显高于对照组P<0.01,差异有统计学意义,降结肠、直肠-乙状结肠交界处MC数量与对照组比较P<0.05,差异有统计学意义。结论:在IBS-D中C-kit对判断MC的数量是较客观的生物学标记物;该标记物对指导临床采用肥大细胞稳定剂治疗具有实际意义。
Objective: To investigate the expression of C-Kit in diarrhea-predominant irritable bowel syndrome (IBS-D) mast cells (MCs) and provide the basis for individual clinical diagnosis and treatment. Methods: Fifty-six patients with IBS-D diagnosed according to RomeIII from the Second Affiliated Hospital of Baotou Medical University from 2007-01 to 2007-05 were enrolled in this study. Immunohistochemistry was used to detect the expression of C-Kit in different parts of intestinal mucosa In the expression of the situation. Results: There were 32 cases of high expression of C-kit in MC, and the number of MC in ascites, ascending colon was significantly higher than that in control group (P <0.01), the difference was statistically significant. The number of MC in descending colon and recto-sigmoid junction The control group, P <0.05, the difference was statistically significant. Conclusion: C-kit in IBS-D is an objective biomarker for judging the number of MCs. It is of practical significance to guide the clinical treatment with mast cell stabilizer.